2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12A.01 Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm

P1.12A.01 Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm

Back to course

Pdf Summary

The study aimed to evaluate the real-world outcomes and treatment patterns associated with first-line (1L) osimertinib in patients with advanced non-small cell lung cancer (NSCLC) who harbor uncommon, or atypical, epidermal growth factor receptor mutations (EGFRm). It was found that the median real-world progression-free survival (rwPFS) and overall survival (rwOS) were lower in patients with atypical EGFRm compared to those with common mutations. Approximately one-third of the patients transitioned to second-line (2L) treatments after stopping 1L osimertinib, but over half died before receiving 2L treatment. <br /><br />The study highlights that optimal selection of 1L treatment is critical and supports the guideline recommending osimertinib for these patients. Notably, data was consistent with previous literature on outcomes for patients with atypical EFGRm. In the study, 61 patients were analyzed: 31% had tumors with both classical and atypical EGFR mutations, while 69% had atypical mutations only. The most common atypical mutations were L861Q, G719X, and T790M. <br /><br />The results showed that patients with only atypical mutations had shorter median rwPFS (6.2 months) and rwOS (20 months) than those with both mutation types (13.2 and 36.1 months, respectively). At the data cut-off, the median follow-up duration was 10 months. Common second-line treatments in the study included chemotherapy, osimertinib combinations, and other EGFR-TKIs. <br /><br />The study concludes that osimertinib remains a crucial 1L treatment option for advanced NSCLC with atypical EGFRm and recommends further long-term analysis. Though the results support current guidelines, limitations include small sample size and limited follow-up duration, emphasizing the need for continued research in this area. The study was presented at the World Conference on Lung Cancer and was funded by AstraZeneca.

Asset Subtitle

Jorge Nieva

Meta Tag

Speaker Jorge Nieva

Topic Metastatic NSCLC – Targeted Therapy

Keywords

osimertinib

NSCLC

EGFR mutations

real-world outcomes

progression-free survival

overall survival

first-line treatment

second-line treatment

atypical mutations

World Conference on Lung Cancer